Share on LinkedInShare on LinkedIn

ARTICLE · 16 MARCH 2015

Teva Pharmaceuticals v. Sandoz: New Rules For Claim Construction Review

WilmerHale
WilmerHale
Contributor
WilmerHale

WilmerHale

WilmerHale's London office was established more than 40 years ago. With lawyers qualified in the...

View firm profile
Explore more from WilmerHale

On January 20, 2015, the Supreme Court changed the standard under which trial court claim construction rulings will be reviewed on appeal, holding that a trial court's factual findings underlying its claim construction rulings must be given deference.

United StatesIntellectual Property

On January 20, 2015, the Supreme Court changed the standard under which trial court claim construction rulings will be reviewed on appeal, holding that a trial court's factual findings underlying its claim construction rulings must be given deference. Teva Pharm. USA, Inc. v. Sandoz, Inc., 135 S.Ct. 831 (2014). In a 7-2 decision, the Teva Court concluded that a trial court's findings of fact underpinning a claim construction ruling must be reviewed under a "clearly erroneous" standard, rather than under the general de novo standard previously applied by the Federal Circuit.[1] The Teva decision, and its new two-part test for review of claim construction determinations, have important ramifications for patent practitioners.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from